Company & research news
The latest news from Ora Biomedical, longevity biotechnology, and geroscience breakthroughs
News
Want to see our thoughts on all things geroscience? Follow us on Twitter for up to the minute perspectives and insights into the world of longevity biotech!
Matt Kaeberlein on the science of aging with National Geographic
December, 2022
Matt Kaeberlein discusses the future of aging, the Dog Aging Project, and Ora Biomedical’s army of drug discovery robots that will build the world’s largest longevity interventions database on Overheard at National Geographic. Listen to “What Science Tells Us About Living Longer” on Spotify.
Ora Biomedical and the "Rise of the WormBots" featured in Longevity.Technology
December, 2022
Ora Biomedical Inc. CEO and co-founder Mitchell Lee sat down with Longevity.Technology to discuss the need for high-throughput drug discovery to identify and develop the most efficacious healthy aging interventions as part of Longevity Biotech 2.0.
CEO Mitchell Lee on "the business of WormBots" in recent interview
November, 2022
Ora Biomedical CEO and Co-Founder Mitchell Lee sat down with Spannr.com to discuss the latest progress in longevity drug discovery and his path from scientist to leading Ora Biomedical.
Ora Biomedical COB Matt Kaeberlein discusses the "dark matter of aging" at ARDD 2022
October, 2022
Ora Biomedical Co-Founder and Chair of the Board Matt Kaeberlein provides thought provoking insights into new studies that reveal how much aging biology has yet to be understood.
Ora Biomedical Founders show intermittent hypoxia extends lifespan
October, 2022
Ora Biomedical Co-Founders Matt Kaeberlein (Ora Biomedical COB) and Jason Pitt (inventor of the WormBot robotics platform) have a new preprint out! Remarkable lifespan extension under intermittent hypoxia (IHT)! Doubled lifespan under IHT and over 100 day old worms when combined with insulin signaling mutants! Have a look: https://www.biorxiv.org/content/10.1101/2022.10.13.512140v1
Ora Biomedical announces Optispan Ventures as Lead Investor in Pre-Seed Financing
August 29, 2022
Seattle, WA – Ora Biomedical, Inc., is proud to announce an investment deal with Optispan Ventures that includes financing and research headquarters to build a high-throughput longevity drug discovery facility in the Pacific Northwest.
Optispan Ventures is focused on healthspan innovations that will define 21st Century Medicine. “Interventions that target the biology of aging have the potential to dramatically improve quality of life by increasing healthspan – a healthy, disease-free lifespan is the goal. We are pleased to partner with Ora to apply their game-changing Wormbot-AI technology and go far beyond what has previously been possible in this field”, says Stuart McKee, CEO of Optispan.
“Optispan Ventures and Ora Biomedical have a shared vision of revolutionizing how we age” says Ora Biomedical CEO, Dr. Mitchell Lee. “Thanks to our partnership with Optispan, we can accelerate the launch of our longevity drug discovery factory and move one step closer to developing breakthrough healthy aging therapeutics for humans and all other animals we love.” For more information, see full press release
Ora Biomedical introduced to LongBio at 4th Longevity Therapeutics Summit
June, 2022
Matt spoke at the 4th Longevity Therapeutics Summit and introduced the longevity biotech community to Ora Biomedical. The announcement was picked up by Rapamycin News.
Matt discusses high-throughput drug screening at ARDD 2021
September, 2021
Matt discussing high-throughput drug discovery using the WormBot.
‘Ora’ is translated as healthy, alive in Pascuan, the language spoken by the people of Rapa Nui, or Easter Island. This island is known to biologists of aging as the home of rapamycin, a compound with remarkable anti-aging properties in laboratory model systems and currently in clinical trials to become the first broad use gerotherapeutic.
Ora Biomedical, Inc. seeks to realize the full potential of healthy aging therapeutics by developing a new generation of broad use small molecule healthy aging interventions for humans, companion pets, and all other organisms for which prolonged healthy survival is desired. Information on this website pertains to preclinical or clinical candidates in development and has not been reviewed or approved by the Food and Drug Administration.